Last reviewed · How we verify

Pharmacologic Pain Management

University of California, San Francisco · Phase 3 active Small molecule

This drug modulates the activity of the mu-opioid receptor to reduce pain perception.

This drug modulates the activity of the mu-opioid receptor to reduce pain perception. Used for Moderate to severe pain.

At a glance

Generic namePharmacologic Pain Management
Also known asOxycodone Hydrochloride, Hydrocodone Bitartrate and Acetaminophen, Morphine Sulfate, Methadone Hydrochloride, Buprenorphine
SponsorUniversity of California, San Francisco
Drug classOpioid
Targetmu-opioid receptor
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

By binding to the mu-opioid receptor, the drug activates a signaling cascade that ultimately leads to the reduction of pain transmission in the central nervous system. This results in a decrease in the perception of pain, providing relief to patients suffering from moderate to severe pain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results